The global molecular diagnostics market is estimated at USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030, growing at a CAGR of 9.6% during the forecast period. Market expansion is driven by increasing investments in research and development, rising awareness of early disease detection, and the growing importance of personalized medicine.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833
Molecular diagnostics technologies offer rapid, accurate, and highly sensitive detection of diseases, enabling healthcare providers to make informed treatment decisions. As healthcare infrastructure continues to improve in emerging markets, the adoption of molecular testing is expanding across clinical and research settings.
Laboratory Testing Segment Maintains Market Leadership
By test type, laboratory-based tests accounted for the largest share of the molecular diagnostics market in 2024. This dominance is attributed to the widespread use of centralized laboratories equipped with advanced, high-throughput platforms capable of processing large volumes of samples.
Lab-based testing provides superior accuracy, sensitivity, and a broad range of assays, making it essential for complex diagnostic applications such as oncology, genetic screening, and infectious disease detection. Continued advancements in automation and multiplex technologies are further enhancing laboratory efficiency and throughput.
Blood-Based Samples Segment Expected to Grow Rapidly
By sample type, the blood, serum, and plasma segment is projected to be the fastest-growing during the forecast period. These sample types are widely used due to their reliability, ease of collection, and compatibility with various molecular diagnostic platforms.
The growth of liquid biopsy technologies and non-invasive testing methods is further accelerating demand for blood-based diagnostics. As healthcare providers increasingly prioritize minimally invasive procedures, this segment is expected to witness sustained expansion.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=833
North America Leads Global Market
North America represents the largest regional market for molecular diagnostics, supported by a strong healthcare infrastructure and high adoption of advanced diagnostic technologies.
The region faces a significant burden of infectious diseases, cancer, and genetic disorders, which drives demand for accurate and timely diagnostics. Favorable regulatory frameworks, consistent R&D investments, and well-established reimbursement systems further support market growth. Additionally, the presence of leading diagnostic companies and advanced laboratory networks enables widespread adoption of molecular testing across clinical settings.
Competitive Landscape
Key players operating in the molecular diagnostics market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), and DiaSorin S.p.A. (Italy), among others.
These companies are focusing on expanding their product portfolios, enhancing automation capabilities, and forming strategic collaborations to strengthen their market presence and meet the growing demand for advanced molecular diagnostic solutions.